Skip to main content

Danaher Corporation (DHR)

NYSE: DHR · IEX Real-Time Price · USD
301.91
+0.53 (0.18%)
After-hours:Oct 15, 2021 7:43 PM EDT
301.38
0.95 (0.32%)
At close: Oct 15, 4:00 PM
Market Cap215.16B
Revenue (ttm)26.72B
Net Income (ttm)5.45B
Shares Out714.50M
EPS (ttm)7.52
PE Ratio40.09
Forward PE30.86
Dividend$0.78 (0.26%)
Ex-Dividend DateSep 29, 2021
Volume2,958,017
Open301.13
Previous Close300.43
Day's Range300.33 - 302.66
52-Week Range210.71 - 333.73
Beta0.72
AnalystsBuy
Price Target332.29 (+10.3%)
Est. Earnings DateOct 21, 2021

About DHR

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to t...

IndustryHealth Care Equipment & Supplies
Founded1969
CEORainer Blair
Employees67,000
Stock ExchangeNYSE
Ticker SymbolDHR
Full Company Profile

Financial Performance

In 2020, Danaher's revenue was $22.28 billion, an increase of 24.42% compared to the previous year's $17.91 billion. Earnings were $3.65 billion, an increase of 21.21%.

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for Danaher stock is "Buy." The 12-month stock price forecast is 332.29, which is an increase of 10.26% from the latest price.

Price Target
$332.29
(10.26% upside)
Analyst Consensus: Buy

News

Danaher (DHR) Earnings Expected to Grow: Should You Buy?

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

Danaher Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainability

WASHINGTON, Oct. 12, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company"), the global science and technology innovator, today released its 2021 Sustainability Report and highlighted the ...

4 days ago - PRNewsWire

Solid U.S. Economic Fundamentals to Drive Wall Street in Q4

We have narrowed down our search to some U.S. corporate behemoths with attractive valuation. These are: CRM, MSFT, WMT, DE, TSLA, DHR, SQ and COST.

4 days ago - Zacks Investment Research

Why Danaher (DHR) Could Beat Earnings Estimates Again

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 week ago - Zacks Investment Research

Danaher Corp (DHR) Sees Hammer Chart Pattern: Time to Buy?

Danaher Corp (DHR) has been struggling lately, but the selling pressure may be coming to an end soon.

1 week ago - Zacks Investment Research

3 Reasons Growth Investors Will Love Danaher (DHR)

Danaher (DHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

1 week ago - Zacks Investment Research

Looking for Earnings Suprise? Play These 5 Stocks

Bet big on the concept positive earnings surprise rather than earnings growth through these 5 stocks.

Other symbols:BYDCRMPNCTJX
2 weeks ago - Zacks Investment Research

Down 6.2% in 4 Weeks, Here's Why Danaher (DHR) Looks Ripe for a Turnaround

Danaher (DHR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...

2 weeks ago - Zacks Investment Research

Here's How Much $100 Invested In Danaher 15 Years Ago Would Be Worth Today

Danaher (NYSE:DHR) has outperformed the market over the past 90 days by 10.15%, generating a 10.28% return for its investors over the time period. Now, given this information, it may seem like price app...

2 weeks ago - Benzinga

Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4%...

ATLANTA, Sept. 28, 2021 /PRNewswire/ -- Beckman Coulter today announced the launch of its DxU Iris Workcell at the AACC Annual Scientific Meeting & Clinical Lab Expo.

2 weeks ago - PRNewsWire

Fed Gives Bond-Buy Tapering Signal Without Timeline: 5 Picks

We have narrowed down our search to five U.S. corporate behemoths that have strong growth potential for the rest of 2021. These are: AAPL, MSFT, NVDA, DHR and COST.

Other symbols:AAPLCOSTMSFTNVDA
3 weeks ago - Zacks Investment Research

Danaher Schedules Third Quarter 2021 Earnings Conference Call

WASHINGTON, Sept. 21, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 ...

3 weeks ago - PRNewsWire

Investing in Water ETFs

An in-depth look at the leading water ETFs in the U.S stock market.

1 month ago - The Motley Fool

Forget Earnings Growth, Focus on Beat With These 5 Stocks

Inside the top-ranked stocks that can beat earnings estimates in their next releases.

Other symbols:CROXSONOTJXWEN
1 month ago - Zacks Investment Research

Danaher Announces Quarterly Dividends

WASHINGTON, Sept. 14, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.21 per share of its common sto...

1 month ago - PRNewsWire

Top 5 High-Flying Low-Beta Stocks for a Volatile September

We have narrowed down our search to five large-cap low-beta stocks that have provided double-digit returns in the past three months. These are: DHR, COST, CARR, MSI, and RSG.

Other symbols:CARRCOSTMSIRSG
1 month ago - Zacks Investment Research

Huntington's Jill Garvey on the stocks presenting opportunity amid fears of rising rates

Jill Garvey, Senior Vice President & Senior Wealth Strategist at Huntington Private Bank, joins Worldwide Exchange to discuss her market outlook.

Other symbols:BKNGPRU
1 month ago - CNBC Television

3 Red-Hot Healthcare Stocks to Buy in September

These businesses are firing on all cylinders.

Other symbols:EDITVEEV
1 month ago - The Motley Fool

Danaher (DHR) Gains As Market Dips: What You Should Know

Danaher (DHR) closed at $332.43 in the latest trading session, marking a +0.3% move from the prior day.

1 month ago - Zacks Investment Research

SCIEX Builds on Cadence of Innovation in Biopharma With Biologics Explorer

FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX builds on cadence of innovation in biopharma with Biologics Explorer, enabling protein characterization analysis for the ZenoTOF 7600 system

1 month ago - Business Wire

SCIEX Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 System

FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX presents the latest capillary electrophoresis solution, the BioPhase 8800 system, the only multi-capillary system for CE-SDS.

1 month ago - Business Wire

Danaher Completes Acquisition of Aldevron

WASHINGTON , Aug. 30, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of Aldevron. As previously announced, Aldevron will operate as a ...

1 month ago - PRNewsWire

10 Best Stocks to Buy if ESG Investing Is Your Thing

If you're into ESG investing and are looking for stocks to buy, Morningstar created a portfolio of ESG mutual funds. Here are 10 solid ideas.

1 month ago - InvestorPlace

7 Stocks to Buy to Cash In on Activist Investor Engine No. 1's New ETF

Engine No. 1 forced Exxon to give the impact investment group at least two seats on its board. Here are 7 stocks to buy from its new ETF.

Other symbols:CRMHDNKENVDAPG
1 month ago - InvestorPlace

Danaher (DHR) Stock Rise 25% in 3 Months: What's Driving It?

Danaher (DHR), with a 25% rise in shares in the past three months, benefits from strong demand, solid product offerings and synergies from buyouts. Shareholder-friendly policies add to its appeal.

1 month ago - Zacks Investment Research